The distribution of the metastatic subtypes was 52.7, 13.8, 7.4, or 11.7% in hormone-receptor-positive/HER2-negative (HR+/HER2–), HR+/HER2+, HR–/HER2+ or triple-negative breast cancer (TNBC) (Fig. 4). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.